GENZYME'S BONE CARE BUY WINS SHAREHOLDER APPROVAL

It looks like Genzyme's latest corporate acquisition is on track to come through. The Cambridge company said today that shareholders of Bone Care International approved the $719 million sale of their business to Genzyme. The deal will become effective July 1. Genzyme will acquire the Middleton, Wis., company to gain access to its kidney-related treatments. Genzyme is also acquiring Bone Care's $119 million in cash, and estimates the net deal will cost about $600 million.

Boston Business Journal (http://boston.bizjournals.com/boston/stories/2005/06/27/daily62.html)